NewsBenzinga노바티스, 재발성 다발성 경화증 치료제 리미브루티닙이 연간 재발률을 35.2%, 31.2% 낮춘다고 발표···3상 REMODEL-1, REMODEL-2 연구 결과 노바티스, 재발성 다발성 경화증 치료제 리미브루티닙이 연간 재발률을 35.2%, 31.2% 낮춘다고 발표···3상 REMODEL-1, REMODEL-2 연구 결과 Benzinga 2026.10.23 16:44 (GMT+0) Open on Benzinga Other news Airbnb Co-Founder Joe Gebbia Says He Modernized Federal Retirement System In 6 Months for $1.5 Million After Contractors Spent $100 Million NVIDIA's Jensen Huang Crisis Threatens to Rewrite the Rules of the AI Boom Mondelez's Multi-Million Portfolio Shift: Unloads French Bakery and Cereal Bars Business Ur-Energy Begins Fieldwork For Baseline Studies At Its Lost Solider Project; Will Take Construction Decision For Potential Third Mine After Technical Report Alibaba Is Facing a Perfect Storm, and Q2 Earnings Won’t Be a Magical Fix for BABA Stock CME Stock: Is Wall Street Bullish or Bearish?
Airbnb Co-Founder Joe Gebbia Says He Modernized Federal Retirement System In 6 Months for $1.5 Million After Contractors Spent $100 Million
Ur-Energy Begins Fieldwork For Baseline Studies At Its Lost Solider Project; Will Take Construction Decision For Potential Third Mine After Technical Report